dijous, 19 de febrer del 2015

C.R. Bard scores reimbursement win for Lutonix




The U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix drug-coated balloon






C.R. Bard (NYSE:BCR) said today that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix drug-coated balloon, which won FDA approval earlier this month.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/180EuE0

Cap comentari:

Publica un comentari a l'entrada